Allison Ross Eckard1, Grace A McComsey2. 1. Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina. 2. University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs). This article comprehensively reviews available data and summarizes our current understanding of the topic. RECENT FINDINGS: Recent studies support the concept that weight gain and treatment emergent obesity are worse with INSTI-based regimens, particularly dolutegravir. Women and nonwhites appear to be the most at risk, and the accompanying nucleoside reverse transcriptase inhibitor may play a role. Lipohypertrophy, an abnormal accumulation of visceral fat and/or ectopic fat depots, continues to be a problem among PLWH, but the role of INSTIs is inconsistent. The pathogenesis of weight gain and changes in body composition in HIV, especially with INSTIs, is poorly understood but may lead to serious comorbidities, such as cardiovascular disease and diabetes. SUMMARY: Although INSTI-based regimens are highly efficacious for viral suppression, they appear to cause more weight gain and treatment emergent obesity than non-INSTI-based regimens and may increase the risk of weight-related comorbidities. More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication.
PURPOSE OF REVIEW: Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs). This article comprehensively reviews available data and summarizes our current understanding of the topic. RECENT FINDINGS: Recent studies support the concept that weight gain and treatment emergent obesity are worse with INSTI-based regimens, particularly dolutegravir. Women and nonwhites appear to be the most at risk, and the accompanying nucleoside reverse transcriptase inhibitor may play a role. Lipohypertrophy, an abnormal accumulation of visceral fat and/or ectopic fat depots, continues to be a problem among PLWH, but the role of INSTIs is inconsistent. The pathogenesis of weight gain and changes in body composition in HIV, especially with INSTIs, is poorly understood but may lead to serious comorbidities, such as cardiovascular disease and diabetes. SUMMARY: Although INSTI-based regimens are highly efficacious for viral suppression, they appear to cause more weight gain and treatment emergent obesity than non-INSTI-based regimens and may increase the risk of weight-related comorbidities. More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication.
Authors: Corrilynn O Hileman; Bruce Kinley; Valeska Scharen-Guivel; Kathy Melbourne; Javier Szwarcberg; Janet Robinson; Michael M Lederman; Grace A Mccomsey Journal: J Infect Dis Date: 2015-01-12 Impact factor: 5.226
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Jeffrey L Lennox; Edwin Dejesus; Daniel S Berger; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Jing Zhao; Hong Wan; Christopher L Gilbert; Hedy Teppler; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J Dinubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar Journal: J Acquir Immune Defic Syndr Date: 2010-09 Impact factor: 3.731
Authors: Paula Debroy; Myung Sim; Kristine M Erlandson; Julian Falutz; Carla M Prado; Todd T Brown; Giovanni Guaraldi; Jordan E Lake Journal: J Antimicrob Chemother Date: 2019-04-01 Impact factor: 5.790
Authors: Lucia Taramasso; Elena Ricci; Barbara Menzaghi; Giancarlo Orofino; Simone Passerini; Giordano Madeddu; Canio Vito Martinelli; Giuseppe Vittorio De Socio; Nicola Squillace; Stefano Rusconi; Paolo Bonfanti; Antonio Di Biagio Journal: Open Forum Infect Dis Date: 2017-11-03 Impact factor: 3.835
Authors: Sergio Setsuo Maeda; Barbara Santarosa Emo Peters; Lígia Araújo Martini; Hannah Karen Moreira Antunes; Maria Cristina Gonzalez; Henrique Pierotti Arantes; Carla M Prado; Camila Lemos Pinto; Iana Mizumukai de Araújo; Francisco José Albuquerque de Paula; Joao Lindolfo Cunha Borges; Ben-Hur Albergaria; Marcela Ushida; Guilherme Cardenaz de Souza; Laura Maria Carvalho de Mendonça; Mirley do Prado; Marcelo de Medeiros Pinheiro Journal: Adv Rheumatol Date: 2022-03-20
Authors: Gabriel Spieler; Andrew O Westfall; Dustin M Long; Andrea Cherrington; Greer A Burkholder; Nicholas Funderburg; James L Raper; Edgar T Overton; Amanda L Willig Journal: AIDS Date: 2022-08-10 Impact factor: 4.632
Authors: Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Mariana Bucovsky; Elizabeth Shane; Michael T Yin; Ryan D Ross Journal: Bone Date: 2021-09-20 Impact factor: 4.626
Authors: Sally B Coburn; Jodie Dionne-Odom; Maria L Alcaide; Caitlin A Moran; Lisa Rahangdale; Elizabeth T Golub; Leslie Stewart Massad; Dominika Seidman; Katherine G Michel; Howard Minkoff; Kerry Murphy; Todd T Brown; Kala Visvanathan; Bryan Lau; Keri N Althoff Journal: J Womens Health (Larchmt) Date: 2022-01-17 Impact factor: 2.681
Authors: Laurence Slama; Benjamin W Barrett; Alison G Abraham; Frank J Palella; Lawrence Kingsley; Jean Paul Viard; Jordan E Lake; Todd T Brown Journal: AIDS Date: 2021-08-01 Impact factor: 4.632
Authors: Rebecca Zash; Ellen C Caniglia; Modiegi Diseko; Gloria Mayondi; Judith Mabuta; Rebecca Luckett; G Justus Hofmeyr; Chelsea Morroni; Doreen Ramogola-Masire; Paige L Williams; Chloe Zera; Blair J Wylie; Joseph Makhema; Shahin Lockman; Roger L Shapiro Journal: J Int AIDS Soc Date: 2021-06 Impact factor: 5.396